GAO Rongyu, ZHANG Jie, SUN Xianyong, HUANG Xudong
滨州医学院学报. 2018, 41(3): 185-187.
Objective To analyze the macular pigment optical density (MPOD) and the multifocal ERG (mf-ERG) changes after pharmacological intervention on variant types of age-related macular degeneration (AMD) patients,and to investigate the impact of macular pigment on visual functions thus providing new clinical indicators in prevention,diagnosis and post-treatment monitoring as well as follow-up visit for AMD patients.Methods Fifty-two eyes(48 cases) patients undergoing fluorescence fundus angiography(FFA)and optical coherence tomography (OCT) were identified as Age-Related Macular Degeneration (AMD) in our hospital from Feb,2015 to May,2016.Twenty-four eyes of 24 cases with dried AMD were treated as group A and 28 eyes of 24 cases with wet AMD were treated as group B.There were 28 male cases and 20 female cases with the eyesight from 0.1 to 0.5.According to whether lutein supplement,All cases were divided randomly into group A1 (lutein),A2,B1 (lutein),and B2.Lutein was administered for 3 months.The MPOD were measured by the MPD mode of the non-mydriatic fundus camera ZEISS Visucam 500 before and after treatment.And The P1 wave and the 1 loop amplitude of the mf-ERG were measured by retinal electrophysiology manufactured by German Roland Company. The impact of macular pigment on visual function of AMD patients were evaluated and statistical analysis was made with SPSS17.0 statistical software.The measurement data were compared with t test and P<0.05 showed the difference was statistical significant.Results The MPOD of group A1 and group A2 before treatment were (0.223±0.135)du and (0.213±0.142)du respectively,with no statistical difference (P>0.05). The post-treatment MPOD of group A1 and group A2 were (0.266±0.189) du and (0.204±0.127) du respectively ,with statistical difference compared with the prior treatment (P<0.05).The prior-treatment MPOD of group B1 and group B2 were (0.169±0.103) du and (0.157±0.137) du respectively ,with no statistical difference (P>0.05).The post-treatment MPOD of group B1 and group B2 were (0.201±0.122) du, (0.132±0.097) du respectively ,with statistical difference compared with the prior treatment (P<0.05).The P1 wave 1 loop amplitude of group A1and group A2 before treatment were (60.42±18.545) and (58.45±20.13) respectively, with no statistical significance of difference (P>0.05).The post-treatment P1wave 1 loop amplitude of group A1and group A2 were (75.53±19.86) and (62.72±20.31) respectively, with statistical difference compared with the prior treatment (P<0.05).The prior-treatment P1wave 1 loop amplitude of group B1and group B2 were (47.44±16.58) and (47.26±16.08) respectively, with no statistical difference in two groups (P>0.05). The post-treatment P1wave 1 loop amplitude of group B1and group B2 were (58.11±16.22) and (50.49±14.41) respectively ,with statistical difference compared with the prior treatment (P<0.05).Conclusion AMD aggravates with the severity of lesions, the density of macular pigment decreases, and mf-ERG amplitude is lowered.The application of lutein can effectively improve the density of macular pigment and protect the visual function of patients with AMD.